Despite differences in the chemical properties of bortezomib, MG-132, and MLN-2238, treatment with these PIs led to the recurrent dysregulation of 12 genes (e.g. BAG3, DNAJB1, HMOX1) in cell lines representing multiple cancer types. This evidence concerns the gene HMOX1 and cancer.